Antibodies Against Complement Components: Relevance for the Antiphospholipid Syndrome—Biomarkers of the Disease and Biopharmaceuticals

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Current Rheumatology Reports

• Publication date

  2017-06-19

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/s11926-017-0669-1PMID 28631067
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A 3-year follow-up of a patient with acute renal failure caused by thrombotic microangiopathy related to antiphospholipid syndrome: case report

  2017cited by this paper
• Complement Inhibition for Prevention and Treatment of Antibody-Mediated Rejection in Renal Allograft Recipients.

  2016cited by this paper
• Proinflammatory proteins in female and male patients with primary antiphospholipid syndrome: preliminary data

  2016cited by this paper
• Catastrophic antiphospholipid syndrome (CAPS): Descriptive analysis of 500 patients from the International CAPS Registry.

  2016cited by this paper
• Autoantibodies against a complement component 1 q subcomponent contribute to complement activation and recurrent thrombosis/pregnancy morbidity in anti-phospholipid syndrome.

  2016cited by this paper
• New milestones ahead in complement-targeted therapy.

  2016cited by this paper
• A case of relapsing and refractory catastrophic anti-phospholipid syndrome successfully managed with eculizumab, a complement 5 inhibitor.

  2016cited by this paper
• Antiphospholipid syndrome.

  2016cited by this paper
• Complement activation is a crucial pathogenic factor in catastrophic antiphospholipid syndrome

  2016cited by this paper
• Therapeutic complement inhibition in complement-mediated hemolytic anemias: Past, present and future.

  2016cited by this paper
• 189Mechanistic evidence for incomplete terminal pathway inhibition under eculizumab during strong complement activation

  2016cited by this paper
• Eculizumab treatment in pregnancy complicated with APS – Effects on mother and infant

  2016cited by this paper
• Design and preclinical characterization of ALXN1210: A next generation anti-C5 monoclonal antibody with improved pharmacokinetics and duration of action

  2016cited by this paper
• Catastrophic antiphospholipid syndrome: The current management approach.

  2016cited by this paper
• Delineating the deranged immune system in the antiphospholipid syndrome.

  2016cited by this paper
• Complement in therapy and disease: Regulating the complement system with antibody-based therapeutics.

  2015cited by this paper
• Factor H Autoantibodies in Patients with Antiphospholipid Syndrome and Thrombosis

  2015cited by this paper
• Eculizumab as rescue therapy in severe resistant lupus nephritis

  2015cited by this paper
• Anti–Factor H Autoantibodies in C3 Glomerulopathies and in Atypical Hemolytic Uremic Syndrome: One Target, Two Diseases

  2015cited by this paper
• Eculizumab treatment during pregnancy does not affect the complement system activity of the newborn.

  2015cited by this paper
• Adalimumab-induced remission of anterior scleritis: a very rare late manifestation of Takayasu arteritis.

  2015cited by this paper
• 14th International Congress on Antiphospholipid Antibodies Task Force. Report on antiphospholipid syndrome laboratory diagnostics and trends.

  2014cited by this paper
• Obstetric antiphospholipid syndrome: a recent classification for an old defined disorder.

  2014cited by this paper
• Are complement deficiencies really rare? Overview on prevalence, clinical importance and modern diagnostic approach.

  2014cited by this paper
• Genetic variants in C5 and poor response to eculizumab.

  2014cited by this paper
• Eculizumab for salvage treatment of refractory antibody-mediated rejection in kidney transplant patients: case reports.

  2013cited by this paper
• Autoantibodies against complement components and functional consequences.

  2013cited by this paper
• Protein therapeutics (introduction to biopharmaceuticals)

  2013cited by this paper
• Targeting the complement system in systemic lupus erythematosus and other diseases.

  2013cited by this paper
• Eculizumab in renal transplantation.

  2013cited by this paper
• Case report: Eculizumab rescue of severe accelerated antibody-mediated rejection after ABO-incompatible kidney transplant.

  2012cited by this paper
• Much more than thrombosis and pregnancy loss: the antiphospholipid syndrome as a 'systemic disease'.

  2012cited by this paper
• Brief report: induction of sustained remission in recurrent catastrophic antiphospholipid syndrome via inhibition of terminal complement with eculizumab.

  2012cited by this paper
• Obstetric and vascular APS: Same autoantibodies but different diseases?

  2012cited by this paper
• C6 knock-out mice are protected from thrombophilia mediated by antiphospholipid antibodies

  2012cited by this paper
• Obstetric antiphospholipid syndrome.

  2012cited by this paper
• Recurrent venous thromboembolism while on anticoagulant therapy.

  2012cited by this paper
• Eculizumab for the treatment of de novo thrombotic microangiopathy post simultaneous pancreas-kidney transplantation--a case report.

  2011cited by this paper
• Complement activation by (auto-) antibodies.

  2011cited by this paper
• Beta 2 glycoprotein 1 (beta 2GPI), the major target in anti phospholipid syndrome (APS), regulates complement activation on the level of C3/C3b

  2011cited by this paper
• β₂-glycoprotein I, the major target in antiphospholipid syndrome, is a special human complement regulator.

  2011cited by this paper
• Inhibiting the C5-C5a receptor axis.

  2011cited by this paper
• Emerging biological drugs: a new therapeutic approach for Systemic Lupus Erythematosus. An update upon efficacy and adverse events.

  2011cited by this paper
• Management of refractory cases of catastrophic antiphospholipid syndrome.

  2011cited by this paper
• Anti-C1q antibodies are associated with systemic lupus erythematosus global activity but not specifically with nephritis: a controlled study of 126 consecutive patients.

  2011cited by this paper
• Complement activation on platelets: implications for vascular inflammation and thrombosis.

  2010cited by this paper
• Eculizumab and renal transplantation in a patient with CAPS.

  2010cited by this paper
• Serum complement activation on heterologous platelets is associated with arterial thrombosis in patients with systemic lupus erythematosus and antiphospholipid antibodies

  2009cited by this paper
• Complement component 5a (C5a).

  2009cited by this paper
• Anti-C1q autoantibodies.

  2008cited by this paper
• High-sensitivity C-reactive protein: discriminator between patients with primary and secondary antiphospholipid syndrome.

  2008cited by this paper
• C1q Binds Phosphatidylserine and Likely Acts as a Multiligand-Bridging Molecule in Apoptotic Cell Recognition1

  2008cited by this paper
• International Consensus Statement on an Update of the Classification Criteria for Definite Antiphospholipid Syndrome(APS)

  2008cited by this paper
• Complement activation in patients with primary antiphospholipid syndrome

  2008cited by this paper
• Complement activation in anti-phospholipid syndrome: a clue for an inflammatory process?

  2007cited by this paper
• Complement deficiencies and systemic lupus erythematosus

  2007cited by this paper
• International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS)

  2006cited by this paper
• Platelet C4d is highly specific for systemic lupus erythematosus.

  2006cited by this paper
• Strategies of therapeutic complement inhibition.

  2006cited by this paper
• Requirement of activation of complement C3 and C5 for antiphospholipid antibody-mediated thrombophilia.

  2005cited by this paper
• Complement Activation: A Novel Pathogenic Mechanism in the Antiphospholipid Syndrome

  2005cited by this paper
• A novel inhibitor of the alternative complement pathway prevents antiphospholipid antibody-induced pregnancy loss in mice.

  2005cited by this paper
• Thrombus formation induced by antibodies to beta2-glycoprotein I is complement dependent and requires a priming factor.

  2005cited by this paper
• Activation of complement mediates antiphospholipid antibody-induced pregnancy loss

  2003cited by this paper
• Complement C5a receptors and neutrophils mediate fetal injury in the antiphospholipid syndrome.

  2003cited by this paper
• Complement activation as a mediator of antiphospholipid antibody induced pregnancy loss and thrombosis

  2002cited by this paper
• Complement C3 Activation Is Required for Antiphospholipid Antibody-induced Fetal Loss

  2002cited by this paper
• IgG subclass distribution of antibodies against beta(2)-GP1 and cardiolipin in patients with systemic lupus erythematosus and primary antiphospholipid syndrome, and their clinical associations.

  2001cited by this paper
• Anti-Beta 2-glycoprotein I antibody isotype and IgG subclass in antiphospholipid syndrome patients.

  1999cited by this paper
• The first subcomponent of complement, C1q, triggers the production of IL-8, IL-6, and monocyte chemoattractant peptide-1 by human umbilical vein endothelial cells.

  1998cited by this paper
• IgG2 restriction of anti-beta2-glycoprotein I as the basis for the association between IgG2 anticardiolipin antibodies and thrombosis in the antiphospholipid syndrome: comment on the article by Sammaritano et al.

  1998cited by this paper
• Human Umbilical Vein Endothelial Cells and Monocyte Chemoattractant Peptide-1 by C 1 q , Triggers the Production of IL-8 , IL-6 , The First Subcomponent of Complement

  1998cited by this paper
• Anticardiolipin IgG subclasses: association of IgG2 with arterial and/or venous thrombosis.

  1997cited by this paper
• Enrichment of antibodies against phospholipids in circulating immune complexes (CIC) in the anti‐phospholipid syndrome (APLS)

  1997cited by this paper
• The antiphospholipid syndrome

  1995cited by this paper
• Human Umbilical Vein Endothelial Cells Synthesize Functional C3, C5, C6, C8 and C9 In Vitro

  1991cited by this paper
• Cellular and Molecular Immunology

  1991cited by this paper

• Activated Complement System’s Impact in Antiphospholipid Syndrome Thrombosis: From Pathophysiology to Treatment

  2025cites this paper
• Complement biology for hematologists

  2023cites this paper
• Catastrophic antiphospholipid syndrome accompanied by complement regulatory gene mutation.

  2023cites this paper
• Antiphospholipid antibodies in healthy Serbian middle-aged subjects: Preliminary data

  2022cites this paper
• Antiphospholipid antibodies in patients with Graves’ orbitopathy: preliminary data

  2021cites this paper
• Impact of Autoantibodies to Complement Components on the Disease Activity in SLE.

  2021cites this paper
• Anti-annexin A5 antibodies and 25-hydroxy-cholecalciferol in female patients with primary antiphospholipid syndrome

  2018cites this paper